A Phase 3 clinical trial into the efficacy of a fish-oil-derived drug called Epanova has been discontinued. The trial was designed to establish the use of the drug, a formulation of two omega-3 fatty acids, as an adjunct to statins for heart disease.

Weiterlesen...